DOTS and DOTS-Plus in Hong Kong [2]

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 1, 2003, Pages 99-100

  Yew, W W ^a   Tam, C M ^b  

^a GRANTHAM HOSPITAL   (Hong Kong)

^b DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

HONG KONG; HUMAN; LETTER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SPUTUM CULTURE; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, MICROBIAL; HONG KONG; HUMANS; POPULATION SURVEILLANCE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0037248183     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Kam K M, Yip C W. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong 1986-1999, after implementation of directly observed treatment. Int J Tuberc Lung Dis 2001; 5: 815-823.
2. Espinal M A, Gupta R, Raviglione M C. The future may not be so dark. Int J Tuberc Lung Dis 2001; 5: 787-788.
3. Chan S L, Wong P C, Tam C M. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong. Tubercle Lung Dis 1994; 75: 245-250.
4. Yew W W, Kwan S Y L, Ma W K, Aung M K, Chau P Y. In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis. J Antimicrob Chemother 1990; 26: 227-236.
5. Yew W W, Chan C K, Chau C H, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-751.
6. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210 (Rev 1). Geneva: WHO, 1997.
7. Iseman M D. Treatment and implications of multidrug-resistant tuberculosis in the 21st century. Chemotherapy 1999; 45 (Suppl 2): 34-40.
8. Espinal M A, Laszlo A, Simonsen L, et al. World Health Organization - International Union Against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
9. World Health Organization Western Pacific Regional Office. Regional strategic plan to stop TB in the Western Pacific, Manila, Philippines. Manila: WPRO, 2000.
10. Grimaldo E R, Tupasi T E, Rivera A B, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5: 546-550.